Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00063154 |
The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer |
Drug: rhuMAb 2C4 (pertuzumab) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Arizona Cancer Center | |
Scottsdale, Arizona, United States, 85258 | |
Arizona Cancer Center | |
Tucson, Arizona, United States, 85724-5024 | |
United States, California | |
University of California Davis Cancer Center | |
Sacramento, California, United States, 95817 | |
Cedars-Sinai Comprehensive Cancer Center | |
Los Angeles, California, United States, 90048 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
Memorial-Sloan Kettering Cancer Center | |
New York, New York, United States, 10021-6007 | |
United States, Tennessee | |
Vanderbilt Ingram Cancer Center | |
Nashville, Tennessee, United States, 37232-5536 | |
United States, Texas | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030-4009 |
Study ID Numbers: | TOC2572g |
Study First Received: | June 20, 2003 |
Last Updated: | August 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00063154 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Lung cancer |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases Non-small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung Recurrence Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |